Danish biotechnology company MinervaX ApS and Wacker Biotech, a contract development and manufacturing organisation (CDMO) owned by German chemical company Wacker Chemie AG (ETR:WCH), on Tuesday announced a collaboration to manufacture MinervaX's Group B Streptococcus (GBS) vaccine.

GBS is a major cause of life-threatening infections in newborns and can also affect pregnant women and older adults. There is a significant unmet medical need for a vaccine to prevent these infections.

MinervaX's vaccine candidate is a novel protein-based vaccine that has shown promising results in clinical trials. The company is preparing to start Phase III trials.

Wacker Biotech will manufacture the active ingredients of the vaccine and ensure stable commercial supply. This collaboration aims to address the urgent need for a GBS vaccine.